- Home
- STX vs NVO Comparison
STX vs NVO Comparison
Compare STX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | NVO |
|---|---|---|
| Founded | 1978 | 1923 |
| Country | Singapore | Denmark |
| Employees | N/A | 69500 |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 197.4B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | STX | NVO |
|---|---|---|
| Price | $853.20 | $42.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 11 |
| Target Price | ★ $604.14 | $51.00 |
| AVG Volume (30 Days) | 3.0M | ★ 10.9M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 0.46% | ★ 3.19% |
| EPS Growth | ★ 328.48 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | ★ $7,384,000,000.00 | N/A |
| Revenue This Year | $27.73 | N/A |
| Revenue Next Year | $25.06 | $3.70 |
| P/E Ratio | $111.85 | ★ $13.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $124.63 | $35.12 |
| 52 Week High | $966.80 | $81.44 |
Technical Indicators
Market Signals| Indicator | STX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 46.75 |
| Support Level | $695.14 | $35.49 |
| Resistance Level | N/A | $50.30 |
| Average True Range (ATR) | 48.64 | 1.15 |
| MACD | -3.37 | -0.45 |
| Stochastic Oscillator | 57.11 | 27.11 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.